First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c01052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Zhen Qiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing100071, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Epilepsy, Nerve Tissue Proteins, Membrane Glycoproteins. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Capital Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
We report the first-in-human evaluation of [18F]BIBD-181, a novel SV2A tracer designed with a fluoropropyl side chain to enable mild, automated radiosynthesis. A fully automated cGMP-compliant production process was developed on a commercial synthesizer, yielding the tracer with >95% radiochemical purity and molar activity >130 GBq/μmol. In eight healthy volunteers, [18F]BIBD-181 demonstrated excellent safety, rapid brain penetration peaking at 15 s post-injection, and a regional uptake pattern consistent with known synaptic vesicle glycoprotein 2A (SV2A) distribution (pallidum SUV = 2.01 ± 0.57 at 30 min). The effective dose was 2.7 μSv/MBq, with predominant renal clearance and no detectable defluorination. In pilot epilepsy patients, [18F]BIBD-181 positron emission tomography (PET) results revealed focal SV2A reductions that were confined to the epileptogenic lesionsa sclerotic hippocampus in one patient and a focal cortical dysplasia (FCD) in anotherwhereas [18F]FDG showed either extensive ipsilateral temporal hypometabolism or concordant focal hypometabolism, suggesting that SV2A imaging may offer more precise lesion delineation, particularly when [18F]FDG abnormalities extend beyond the true epileptogenic zone. These findings establish [18F]BIBD-181 as a clinically practical SV2A PET tracer with favorable dosimetry, simplified production, and promising utility for epilepsy surgical planning, warranting further validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing100071, China.
- Beijing Institute of Brain Disorders, Beijing Key Laboratory of Innovation and Translation of Central Nervous System Radiopharmaceuticals, Capital Medical University, Beijing100069, China.
- School of Pharmaceutical Science, Capital Medical University, Beijing100069, China.
ORCID-Profile: Xiaobin Zhao, Zehui Wu
Förderung
- Natural Science Foundation of Beijing Municipality
- Capital Medical University
- National Natural Science Foundation of China
Zitieren
APA
Qiao, Z., Li, S., Zhang, Y., Zhao, X., Yang, Z., Sun, X., Chen, H., Cheng, X., Liu, Y., Ai, L., & Wu, Z. (2026). First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c01052
Vancouver
Qiao Z, Li S, Zhang Y, Zhao X, Yang Z, Sun X, et al. First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c01052
BibTeX
@article{Qiao2026,
author = {Qiao, Zhen and Li, Shen and Zhang, Yongzhong and Zhao, Xiaobin and Yang, Zihao and Sun, Xinyu and Chen, Hualong and Cheng, Xuebo and Liu, Yajing and Ai, Lin and Wu, Zehui},
title = {First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c01052}
}
EUVIMED